Clinical trial · Observational
Long-Term Follow-up Study
An Observational Long-Term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
NCT05332054CI-TRIAL-00105295LTFSenrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| B Cell Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| B-Cell Non-Hodgkin's Lymphoma | B-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Refractory B-Cell Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
| Relapsed Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
| Relapsed/Refractory Acute Myeloid Leukemia | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Caribou-sponsored investigational therapy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients who received IP in a Caribou-sponsored, special access program or IIT and provided informed
- description
- consent for the LTFS
- interventionNames
- Biological: Caribou-sponsored investigational therapy
Primary outcomes (13)
- measure
- Incidence of targeted NSAEs
- timeFrame
- 15 Years
- description
- Incidence of targeted NSAEs
- measure
- Frequency of targeted NSAEs
- timeFrame
- 15 Years
- description
- Frequency of targeted NSAEs
- measure
- Duration of targeted NSAEs
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent (by patient or legal representative) obtained prior to study-specific activities/enrollment * Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT * Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion. Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.